TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1780092

Group type: EXPERIMENTAL
Intervention: Nimesulide (one suppository twice a day for 7 days)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Flurbiprofen (one suppository twice a day for 7 days)
Number of subjects: 98
Study: 6801929

Group type: EXPERIMENTAL
Intervention: Forced fluid intake
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fluid deprivation plus DDAVP
Number of subjects: 41

Group type: COMPARATOR
Intervention: Free fluid intake
Number of subjects: 41
Study: 30312118

Group type: EXPERIMENTAL
Intervention: 12-month combined aerobic and resistance exercise program
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study: 28736139

Group type: EXPERIMENTAL
Intervention: Stop TDF therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continue TDF therapy
Number of subjects: 42
Study: 26953856

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program (8-week initial treatment plus a 10-month maintenance phase)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program (10-month maintenance phase)
Number of subjects: 42
Study: 24834811

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1066
Study: 21845596

Group type: EXPERIMENTAL
Intervention: Continuation haloperidol (0.5‐5 mg daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.5‐5 mg daily)
Number of subjects: 44
Study: 19492717

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: iBond
Number of subjects: 38

Group type: COMPARATOR
Intervention: One-Step Plus
Number of subjects: 38
Study: 17872849

Group type: EXPERIMENTAL
Intervention: Swab Group (n = 300): Cervix wiped with a cotton swab before Pap smear
Number of subjects: 616

Group type: COMPARATOR
Intervention: No Swab Group (n = 316): Cervix not cleaned with a cotton swab before Pap smear
Number of subjects: 616
Study: 14965860

Group type: EXPERIMENTAL
Intervention: Computer program for assessing and training motor coordination
Number of subjects: 11
Study: 11310459

Group type: EXPERIMENTAL
Intervention: Oral ketamine (10 mg/kg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Oral midazolam (0.7 mg/kg)
Number of subjects: 59
Study: 9127921

Group type: EXPERIMENTAL
Intervention: Nonspecific low back pain
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Subgroups of low back pain
Number of subjects: 748
Study: 7885982

Group type: EXPERIMENTAL
Intervention: Saquinavir mesylate (Hoffmann‐La Roche, Nutley, NJ)
Number of subjects: 0
Study: 2438876

Group type: EXPERIMENTAL
Intervention: Grenz rays (3 Gy, once a week for 3 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control skin (untreated)
Number of subjects: 11
Study: 31919889

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 2217

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 2217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2217

Group type: EXPERIMENTAL
Intervention: Tildrakizumab (both doses)
Number of subjects: 2217
Study: 30942862

Group type: EXPERIMENTAL
Intervention: Bicycle exercise under normobaric hypoxia (fraction of inspired oxygen = 15%)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Bicycle exercise under normoxia (fraction of inspired oxygen = 21%)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both hypoxia and normoxia groups
Number of subjects: 29
Study: 28783060

Group type: EXPERIMENTAL
Intervention: Nacadia® therapy garden design
Number of subjects: 0
Study: 25998500

Group type: EXPERIMENTAL
Intervention: Febuxostat (10 mg daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 23003917

Group type: EXPERIMENTAL
Intervention: Initial periodontal treatment (test group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No periodontal therapy (control group, n = 20)
Number of subjects: 40
Study: 20829332

Group type: EXPERIMENTAL
Intervention: Training on mitral regurgitation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Training on symptomatic aortic stenosis
Number of subjects: 86

Group type: COMPARATOR
Intervention: Training on scenario with no cardiac murmur
Number of subjects: 86
Study: 18716365

Group type: EXPERIMENTAL
Intervention: Valsartan monotherapy (VM)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Amlodipine monotherapy (AM)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Valsartan + ACE inhibitor (VA)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Amlodipine + ACE inhibitor (AA)
Number of subjects: 140
Study: 16781297

Group type: EXPERIMENTAL
Intervention: 14 J/cm(2) fluence
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 16 J/cm(2) fluence
Number of subjects: 20
Study: 14653370

Group type: EXPERIMENTAL
Intervention: Acyclovir (Zovirax) with prednisolone
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo with prednisolone
Number of subjects: 91
Study: 10319359

Group type: EXPERIMENTAL
Intervention: Vitamin E (1000 IU daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (soya lecithin)
Number of subjects: 40
Study: 8726762

Group type: EXPERIMENTAL
Intervention: Plastic stent
Number of subjects: 39

Group type: COMPARATOR
Intervention: Expandable metal stent
Number of subjects: 39
Study: 1890479

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intramuscular morphine (IM)
Number of subjects: 42
Study: 6191489

Group type: EXPERIMENTAL
Intervention: Diphencyprone
Number of subjects: 27
Study: 29460955

Group type: EXPERIMENTAL
Intervention: UFOV assessment at one, two and three months' post-stroke
Number of subjects: 42

Group type: COMPARATOR
Intervention: UFOV assessment at three months' post-stroke (Control group)
Number of subjects: 42
Study: 31058771

Group type: EXPERIMENTAL
Intervention: 200 mg/day DHA
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1000 mg/day DHA
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study: 28259476

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: First-line AR-targeted therapy
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Detection of somatic deletion in ctDNA
Number of subjects: 319
Study: 25538174

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) followed by chemotherapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Upfront chemotherapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 105
Study: 23486643

Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Other fluoroquinolones
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonfluoroquinolones
Number of subjects: 64
Study: 22372266

Group type: EXPERIMENTAL
Intervention: Forsus FRD EZ appliance
Number of subjects: 24

Group type: COMPARATOR
Intervention: Activator appliance
Number of subjects: 24
Study: 19366755

Group type: EXPERIMENTAL
Intervention: Fluoroscopic guidance for corticosteroid injections (n=32)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Blind injections using landmarks (n=33)
Number of subjects: 65
Study: 16937961

Group type: EXPERIMENTAL
Intervention: Caffeine-containing supplement (SUPP; n = 17)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (PLAC; n = 20)
Number of subjects: 37
Study: 15252161

Group type: EXPERIMENTAL
Intervention: 4 h infusion of 120 g of mixed AAs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4 h infusion of 50 g of L‐lysine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 h infusion of 240 g of mixed AAs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4 h infusion of 50 g of L‐lysine + L‐arginine (Lys‐Arg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No infusion (control)
Number of subjects: 24
Study: 11182837

Group type: EXPERIMENTAL
Intervention: BloodLink‐Guideline
Number of subjects: 60

Group type: COMPARATOR
Intervention: BloodLink‐Restricted
Number of subjects: 60
Study: 9036797

Group type: EXPERIMENTAL
Intervention: Intravenous cidofovir, 5 mg/kg of body weight, once weekly for 2 weeks and then once every other week
Number of subjects: 48

Group type: COMPARATOR
Intervention: Deferred treatment (no cidofovir until progression documented)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous cidofovir
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous cidofovir with probenecid and saline hydration
Number of subjects: 48
Study: 7639363

Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg intravenously
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg orally
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3281700

Group type: EXPERIMENTAL
Intervention: Gallamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suxamethonium
Number of subjects: 0
Study: 31863134

Group type: EXPERIMENTAL
Intervention: Intraoperative radiographs (IR) assessment by orthopedic trauma surgeons
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postoperative radiograph requests
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postoperative CT requests
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inter-observer reliability
Number of subjects: 30
Study: 29129715

Group type: EXPERIMENTAL
Intervention: Adapted Diabetes Prevention Program Group Lifestyle Balance (DPP GLB) intervention, details on dosage and duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responsive adaptations during intervention delivery, details on dosage and duration not specified.
Number of subjects: 0
Study: 27145396

Group type: EXPERIMENTAL
Intervention: Online Lee Silverman Voice Treatment (LSVT LOUD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Face‐to‐face Lee Silverman Voice Treatment (LSVT LOUD)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Online treatment (nonmetropolitan cohort)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Online treatment (metropolitan cohort)
Number of subjects: 31
Study: 24509430

Group type: EXPERIMENTAL
Intervention: Metoprolol + Reboxetine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ivabradine + Reboxetine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo + Reboxetine
Number of subjects: 19
Study: 23565787

Group type: EXPERIMENTAL
Intervention: Spaced training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategically massed training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomly massed training
Number of subjects: 0
Study: 21161380

Group type: COMPARATOR
Intervention: Fasting for 12 hours before CE (Group A, n = 23)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 2 liters of polyethylene glycol (PEG) (Group B, n = 20)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 4 liters of polyethylene glycol (PEG) (Group C, n = 25)
Number of subjects: 68
Study: 18374304

Group type: EXPERIMENTAL
Intervention: Face-to-face cognitive-behavioral therapy (FTF-CBT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Telemedicine cognitive-behavioral therapy (TV-CBT)
Number of subjects: 128
Study: 17134621

Group type: EXPERIMENTAL
Intervention: Vasopressin (40 IU)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 14500059

Group type: EXPERIMENTAL
Intervention: Standardized modified Burch colposuspension added to planned abdominal sacrocolpopexy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Planned abdominal sacrocolpopexy without Burch colposuspension
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Preoperative urodynamic testing with prolapse reduction
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Standardized questionnaires and physical observations
Number of subjects: 91
Study: 11198206

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin IgG, 0.4 g/kg body weight/day for 5 consecutive days, followed by single booster doses of 0.4 g/kg/day, once a month for 9 months
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin IgG
Number of subjects: 13
Study: 8833099

Group type: EXPERIMENTAL
Intervention: 1 g/kg/day alcohol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 g/kg/day alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 g/kg/day alcohol (control)
Number of subjects: 0
Study: 1428567

Group type: EXPERIMENTAL
Intervention: 0.5% maleate timolol, twice a day for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (untreated contralateral eyes)
Number of subjects: 12
Study: 6776576

Group type: EXPERIMENTAL
Intervention: (‐)‐deprenyl (5‐10 mg/day for 3 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 6
Study: 30308286

Group type: EXPERIMENTAL
Intervention: Daily breath alcohol monitoring with reinforcement for alcohol-negative breath samples
Number of subjects: 19

Group type: COMPARATOR
Intervention: Daily breath alcohol monitoring without reinforcement
Number of subjects: 19

Group type: COMPARATOR
Intervention: Transdermal alcohol monitoring
Number of subjects: 19

Group type: COMPARATOR
Intervention: Self-report data
Number of subjects: 19

Group type: COMPARATOR
Intervention: BrAC monitoring
Number of subjects: 19

Group type: COMPARATOR
Intervention: Transdermal monitoring
Number of subjects: 19

Group type: COMPARATOR
Intervention: Self-report monitoring
Number of subjects: 19
Study: 28114607

Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping (≥180 seconds after delivery)
Number of subjects: 540
Study: 25796293

Group type: EXPERIMENTAL
Intervention: Oxycodone with analgesia information sheet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard postoperative information without analgesia information sheet
Number of subjects: 0
Study: 23389323

Group type: EXPERIMENTAL
Intervention: sertraline hydrochloride (50 mg/d) + active tDCS (2‐mA anodal left/cathodal right prefrontal tDCS, twelve 30‐minute sessions)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: tDCS only (2‐mA anodal left/cathodal right prefrontal tDCS, twelve 30‐minute sessions)
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo/sham tDCS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: tDCS only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: active tDCS
Number of subjects: 120
Study: 20623280

Group type: EXPERIMENTAL
Intervention: Full weightbearing after cementless total hip arthroplasty
Number of subjects: 100

Group type: COMPARATOR
Intervention: Partial weightbearing after cementless total hip arthroplasty
Number of subjects: 100
Study: 19779953

Group type: EXPERIMENTAL
Intervention: vitalHEAT system
Number of subjects: 55

Group type: COMPARATOR
Intervention: Bair Hugger
Number of subjects: 55
Study: 17069818

Group type: EXPERIMENTAL
Intervention: Irbesartan (IRB; 300 mg/d) for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Losartan (10(‐5) mol/L)
Number of subjects: 18

Group type: COMPARATOR
Intervention: LY311727 (10(‐5) mol/L)
Number of subjects: 18
Study: 16898905

Group type: EXPERIMENTAL
Intervention: 0.1% ALA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1% ALA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5% ALA
Number of subjects: 12
Study: 14500434

Group type: EXPERIMENTAL
Intervention: Methylxanthines
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 10194425

Group type: EXPERIMENTAL
Intervention: FAI + ATRA
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: FAI + G-CSF
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: FAI + ATRA + G-CSF
Number of subjects: 215

Group type: COMPARATOR
Intervention: FAI
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: FAI + G-CSF + ATRA
Number of subjects: 215
Study: 8576656

Group type: EXPERIMENTAL
Intervention: Dynorphin 180 micrograms/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dynorphin 60 micrograms/kg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (0 micrograms/kg)
Number of subjects: 21
Study: 2089047

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6106781

Group type: EXPERIMENTAL
Intervention: 2-mercaptoethane sulphonate sodium (mesnum)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isophosphamide alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isophosphamide with mesnum (4 to 8 g/m2)
Number of subjects: 8
Study: 31240727

Group type: EXPERIMENTAL
Intervention: Guided Internet intervention (deprexis)
Number of subjects: 223
Study: 29705674

Group type: EXPERIMENTAL
Intervention: Structured personal care
Number of subjects: 1381

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 1381
Study: 28251722

Group type: EXPERIMENTAL
Intervention: Morning learning session with positive, neutral or negative valenced cues
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Evening learning session with positive, neutral or negative valenced cues
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Relearning with the same word-pairs one week later
Number of subjects: 386

Group type: COMPARATOR
Intervention: Sleep (compared to no sleep)
Number of subjects: 386
Study: 25782657

Group type: COMPARATOR
Intervention: Probiotic milk containing Lactobacillus rhamnosus GG, L acidophilus La-5, and Bifidobacterium animalis subsp. lactis Bb-12, administered from 36 weeks of gestation to 3 months postnatally.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probiotic milk (Lactobacillus rhamnosus GG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probiotic milk and placebo
Number of subjects: 0
Study: 23787030

Group type: EXPERIMENTAL
Intervention: 8-weeks of combination nicotine replacement therapy (NRT) in conjunction with brief counseling (SBIRT framework) (n=23)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (n=17)
Number of subjects: 40
Study: 20947208

Group type: EXPERIMENTAL
Intervention: Prewired electrodes
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional electrodes
Number of subjects: 105
Study: 18787321

Group type: EXPERIMENTAL
Intervention: Group-based resistance and balance training (RBT)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Home-based resistance and balance training (RBT)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Group-based walking
Number of subjects: 167
Study: 16855076

Group type: EXPERIMENTAL
Intervention: Lidocaine (4 mg/kg; maximal dose 300 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen (10/650 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active placebo (diphenhydramine, 50 mg)
Number of subjects: 60
Study: 12806229

Group type: EXPERIMENTAL
Intervention: Total circulatory arrest or low‐flow cardiopulmonary bypass (not specified which is I or C)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 155
Study: 10818327

Group type: EXPERIMENTAL
Intervention: remifentanil + isoflurane (0.6 vol% end-tidal)
Number of subjects: 249

Group type: COMPARATOR
Intervention: remifentanil + propofol (0.1 mg/kg/min)
Number of subjects: 249
Study: 9045235

Group type: EXPERIMENTAL
Intervention: Turbo Spin Echo (TSE) sequences
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional Spin Echo (SE) sequences
Number of subjects: 36
Study: 1891509

Group type: EXPERIMENTAL
Intervention: MCPP (meta‐chlorophenylpiperazine)
Number of subjects: 72
Study: 6623770

Group type: EXPERIMENTAL
Intervention: 5,000 units of subcutaneous heparin three hours preoperatively and every twelve hours thereafter for forty-eight hours
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal saline injections in a similar manner
Number of subjects: 34
Study: 31918039

Group type: EXPERIMENTAL
Intervention: Combined action observation and motor imagery (AO + MI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (unrelated videos with no motor content)
Number of subjects: 20
Study: 31014938

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation (TR) program, breathing and calisthenic exercises, three times a week for 6 weeks, via internet-based video conferences.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 50
Study: 29759717

Group type: EXPERIMENTAL
Intervention: Active LLVNS
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 54
Study: 27658192

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal (CR)
Number of subjects: 72
Study: 24924292

Group type: EXPERIMENTAL
Intervention: NOCTP
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: IPFA
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control
Number of subjects: 230
Study: 22041543

Group type: EXPERIMENTAL
Intervention: Garlic fermented with Monascus pilosus (MGFE)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 19619020

Group type: EXPERIMENTAL
Intervention: Doripenem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 0
Study: 17461902

Group type: EXPERIMENTAL
Intervention: docetaxel (T) 75 mg/m(2), epirubicin (E) 75 mg/m(2), cyclophosphamide (C) 500 mg/m(2) IV
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: docetaxel (T) 100 mg/m(2), epirubicin (E) 100 mg/m(2), cyclophosphamide (C) 500 mg/m(2) IV
Number of subjects: 15
Study: 15033849

Group type: EXPERIMENTAL
Intervention: Antibiotic use in RSV infected children
Number of subjects: 1795

Group type: COMPARATOR
Intervention: RSV infection with risk factors
Number of subjects: 1795
Study: 11243558

Group type: EXPERIMENTAL
Intervention: B&L pinch gauge
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: JTech pinch gauge
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NK pinch gauge
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All pinch gauges
Number of subjects: 40
Study: 9143213

Group type: EXPERIMENTAL
Intervention: Spa therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 121
Study: 8504501

Group type: EXPERIMENTAL
Intervention: Autodecremental overdrive pacing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-energy cardioversion
Number of subjects: 24